Ketamine Therapy in Scotland: NHS and Private (2026)

Scotland's position is unusual and easy to miss, because most UK coverage of ketamine treatment is written from England. The essential fact is that a devolved medicines decision went the other way here: where NICE said no, the Scottish Medicines Consortium said yes with restrictions, so an NHS-funded route exists in Scotland that does not exist in England, Wales or Northern Ireland. This guide sets out what that route covers, what it does not, and what the private and research options look like from Edinburgh or Glasgow.

TL;DR The NHS route in Scotland is esketamine (Spravato), accepted by the SMC for restricted use in treatment-resistant depression and delivered via psychiatrist assessment and local health board arrangements; start by asking your psychiatrist, with a written treatment history in hand. Racemic ketamine infusions are not routinely funded by the NHS anywhere in the UK, so infusions and ketamine-assisted psychotherapy in Scotland are private and self-pay at roughly £300–800 per infusion, or from about £6,000 for a full programme. Trials in Edinburgh and Glasgow are recruiting and free.

The routes at a glance

	NHS esketamine (Scotland)	Private ketamine or KAP	NHS trust, self-funded (Oxford)	Clinical trial
What it is	Spravato nasal spray under supervision, alongside a continuing oral antidepressant	Off-label IV ketamine infusions, sometimes with preparation and integration therapy	Off-label IV ketamine inside an NHS trust's own service	Study medicine under research protocol
Who can use it	Treatment-resistant depression assessed by a psychiatrist under SMC restrictions and health board arrangements	Self-referral is widely accepted, but suitability is established by a full clinical assessment (diagnosis and severity, previous treatment, comorbidity, current medicines and substance use, risk and consent), not by passing an initial screen	Anyone with a referral letter from a GP or psychiatrist, subject to the service's intake rules	Study-specific criteria; strict screening
Cost	Covered by NHS Scotland	£300–800 per infusion; programmes from ~£6,000	£265 per infusion and per initial assessment; budget ~£3,000/year	Free
How to start	Ask your psychiatrist about the pathway in your health board area	Contact the clinic directly	GP or psychiatrist referral letter, then an assessment usually held online	Registry search plus screening

The NHS route: esketamine, via your psychiatrist

The Scottish Medicines Consortium accepted esketamine (SMC2258) for restricted use in treatment-resistant depression under a patient access scheme, implemented through the health boards. NICE, by contrast, did not recommend it in TA854 on cost-effectiveness grounds, a decision that applies in England and Wales and which Northern Ireland endorsed. The result is a genuine postcode difference within one licensed medicine: the detail is in our UK reimbursement guide.

What the restriction turns on is documented treatment resistance: generally, an inadequate response to at least two different antidepressant treatments of adequate dose and duration during the current moderate-to-severe episode. Under the licence, esketamine is then given alongside a continuing oral SSRI or SNRI, and failing two treatments does not by itself guarantee suitability: the assessment weighs diagnosis, comorbidity, current medicines and risk as well. Assessment is by a psychiatrist, and delivery depends on your local health board's arrangements. Two practical implications follow. First, your GP is not the decision-maker but is the door: a referral into secondary care, plus a printout of your medication history, is the useful first ask. Second, the written treatment history (every antidepressant tried in the current episode, with dose, duration and outcome) carries the case. Bring it; it counts for more than anything you say in the room.

If esketamine is approved for you, the sessions are supervised: you self-administer the spray in the clinic, blood pressure is checked before the dose and again at about 40 minutes, and staff observe for sedation, dissociation and other adverse effects until you are clinically stable, roughly two hours is a typical observation period, not a fixed discharge point. You continue an oral antidepressant alongside, and you do not drive or do anything hazardous until the following day, after a restful sleep. Our preparation checklist covers the day in detail.

Safety in brief. Common adverse effects of supervised esketamine include dizziness, dissociation, nausea, headache, sleepiness, altered taste, vertigo, vomiting and a transient rise in blood pressure; rare respiratory depression has been reported. The licence rules out treatment where a blood-pressure or intracranial-pressure rise would pose a serious risk (aneurysmal vascular disease, a previous bleed in the brain, a recent cardiovascular event), and calls for caution with psychosis, a history of mania or bipolar disorder, substance-misuse risk, pregnancy, and interacting medicines such as sedatives or those that raise blood pressure. Screening and monitoring exist to manage exactly these; disclose everything at assessment.

Ketamine infusions: private, and priced like the rest of the UK

The NHS route in Scotland is for esketamine specifically. Racemic ketamine (the generic anaesthetic given as an intravenous infusion) has never been appraised for routine NHS commissioning anywhere in the UK, because its use for depression is off-label. The NHS pilots of racemic ketamine that do exist run at Oxford Health and Central and North West London NHS Foundation Trusts (Magnetar/Blossom reimbursement report, 2025), both in England and reached through NHS referral rather than direct booking.

So in Scotland, infusions and ketamine-assisted psychotherapy mean the private market, on UK terms: roughly £300–800 per infusion, with London typically around £595, and full KAP programmes from about £6,000 for six weeks. Our UK cost comparison and European cost guide collect the published figures.

In our directory, the Scottish private option we have verified is Eulas Clinics in Edinburgh: the city's full picture is in our Edinburgh guide, a ketamine-assisted psychotherapy provider that also lists sites in London and Manchester and publishes a six-week programme from around £6,000. Glasgow is the honest gap: we currently list no private ketamine clinic there; the Glasgow entry in our directory is a hospital trial site, not a treatment service. If you are in the west of Scotland, the realistic private options are travelling to Edinburgh, travelling south, the full list of UK ketamine clinics shows what that opens up, or asking a clinic whether it runs remote consultations with in-person dosing elsewhere. You can compare everything we list at providers in the United Kingdom, and every legal route to ketamine therapy in the UK, including psilocybin and MDMA research, is covered in our UK access guide.

One cross-border option is worth pricing before you commit. Oxford Health NHS Foundation Trust runs a self-funded ketamine service inside the NHS at £265 per infusion and per initial psychiatrist assessment, with £125 per scheduled review, open to patients with a referral letter from a GP or psychiatrist subject to its intake rules, the assessment itself usually happens online, and the service suggests budgeting around £3,000 per year. Genuinely NHS-funded treatment there is limited to Oxfordshire and Buckinghamshire patients referred by its own consultants, but the self-funded route is not catchment-limited. For a Scottish patient an induction course at those prices, travel included, may still undercut a private programme at home: recent consensus describes roughly four to six infusions over two to four weeks as common practice rather than a licensed standard, and Oxford itself plans three to six over three to six weeks, individualised on response. Whether the therapy layer in a KAP programme is worth the difference is a real clinical question, not a settled one: a 2026 systematic review found a heterogeneous evidence base with few randomised trials and few psychotherapy-control groups, so the added benefit of preparation and integration therapy remains uncertain, and it should not be treated as a required component of ketamine treatment.

Whichever you choose, verify before paying. Independent clinics in Scotland are regulated by the Scottish equivalent of the CQC rather than by the CQC itself, so check the clinic's entry on the relevant national register, check the prescriber on the GMC register, get the full course cost in writing, and ask what maintenance costs after the induction. The full checklist is in our clinic-choice guide.

And ask what happens after the induction. Esketamine has a defined induction-and-maintenance schedule with periodic review of continued benefit; IV ketamine has no licensed UK schedule for depression, so any continuation or maintenance is individualised. Either way, expect symptom measurement and an agreed decision point for stopping, continuing or reconsidering treatment, agreed before the course starts, not improvised at its end.

The research route

If cost is the constraint, trials are free by definition: legitimate studies never charge, and many reimburse travel. Scotland is part of one of Europe's busiest psychedelic research scenes: our directory lists NHS Research Scotland in Edinburgh and Queen Elizabeth University Hospital in Glasgow as sites recruiting for NCT06793397, Cybin's Phase 3 study of the deuterated psilocin analogue CYB003 in major depressive disorder. Across the UK, 67 studies are tracked and 12 are active, spanning psilocybin, ketamine, DMT and esketamine.

Screening is strict and enrolment is never guaranteed, so treat trials as an option to check rather than a plan to rely on. Our trials guide explains how phases, placebo and consent work and how to search the registries.

Reviewer's note. This is a useful and accessible overview of treatment routes for people in Scotland, clearly distinguishing supervised intranasal esketamine from off-label racemic ketamine infusions. Its practical comparison is helpful, while concise clinical context on eligibility, monitoring, adverse effects and the uncertain added benefit of psychotherapy is essential for informed decision-making.

— Dr. Christopher Gauci, MD MRCS(Ed) EDAIC, anaesthetist and intensive care specialist, PsyAccess medical reviewers

Frequently asked questions

Can I get ketamine therapy on the NHS in Scotland?

You can get esketamine (Spravato) on the NHS in Scotland if a psychiatrist assesses you as meeting the SMC restrictions for treatment-resistant depression and your health board provides the service. Racemic ketamine infusions are not routinely NHS-funded in Scotland or anywhere else in the UK; the NHS ketamine pilots are in England.

How do I start the NHS esketamine route in Scotland?

Ask your psychiatrist directly about the esketamine pathway in your health board area: do not assume the England picture applies to you. If you are not currently under a psychiatrist, ask your GP for a referral into secondary care and take a written history of every antidepressant tried in the current episode with dose, duration and outcome.

Is there a ketamine clinic in Glasgow?

Not in our directory as of August 2026. The Glasgow record we hold is a hospital trial site rather than a treatment service; the nearest verified private option in Scotland is in Edinburgh. Listings change, so check the UK directory for the current picture before assuming either way.

What does private ketamine therapy cost in Scotland?

At UK market rates: roughly £300–800 per infusion, with full ketamine-assisted psychotherapy programmes from around £6,000 for six weeks. Ask for the full course cost in writing rather than a per-session price, and compare it against the £265 per infusion charged by the NHS trust service in Oxford, which accepts self-funded referrals from outside its area.

Is Spravato the same as ketamine infusions?

No. Spravato is esketamine (the S-enantiomer of the ketamine molecule) given as a nasal spray under its own EU and UK licence for treatment-resistant depression; racemic ketamine contains both R- and S-enantiomers and is generally given intravenously, off-label, when used for depression. Dosing schedules, evidence, monitoring and maintenance pathways differ, and the head-to-head evidence is mostly observational: it does not establish that the two are interchangeable or that one is generally superior. See our side-by-side comparison.

Are there depression or psychedelic trials in Scotland?

Yes, though the active Scottish study is not a ketamine trial. Edinburgh and Glasgow sites are recruiting for a Phase 3 depression study of CYB003, a deuterated psilocin analogue (a serotonergic psychedelic, not ketamine or esketamine); UK-wide, the trial scene does include ketamine and esketamine studies. Participation is free, screening is strict, and enrolment is never guaranteed.

Sources

This guide is for general information only and is not medical advice, a diagnosis, or a recommendation of any treatment. Regulations and prices change; always verify a provider's current registration with the relevant regulator, confirm fees in writing, and discuss your options with a licensed clinician who knows your history. If you are in crisis, contact your local emergency number or a crisis line immediately.

This guide awaits review by a licensed medical professional.

Ketamine Therapy in Scotland: NHS and Private Options (2026)

On this page